Drugs / Fecal Microbiome Transplantation
Fecal Microbiome Transplantation
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06533852 | Jul 2025 → Jan 2029 expected | cirrhosis of liver | Biomedical Research Networking Center (CIBER) | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-01-30 | Shenzhen Xbiome Biotech Co., Ltd. | Results 未知君与北京大学肿瘤医院首次采用健康供体FMT胶囊逆转胃部肿瘤患者PD-1抗体耐药 xbiome.com ↗
该研究发现健康供体肠菌移植胶囊可能能够逆转胃部肿瘤患者的抗PD-1耐药。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-01-30 | Shenzhen Xbiome Biotech Co., Ltd. | 未知君与北京大学肿瘤医院首次采用健康供体FMT胶囊逆转胃部肿瘤患者PD-1抗体耐药 xbiome.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fecal Microbiome Transplantation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06533852 ↗ |
| Known as | Fecal Microbiota Transplantation | “Fecal Microbiota Transplantation (FMT) from healthy subjects to patients with decompensated cirrhosis” NCT06533852 ↗ |
| Known as | FMT | “Fecal Microbiota Transplantation (FMT) from healthy subjects to patients with decompensated cirrhosis” NCT06533852 ↗ |